Gilead Sciences Inc stock page - price, fundamentals, dividends - iOCharts

GILD

70.43
-1.34 (-1.87%)
Gilead Sciences Inc (NASDAQ, USD)
Healthcare >
Drug Manufacturers-General
Market cap
88.35B
Ent value
129.61B
Price/Sales
3.58
Price/Book
4.11
Div yield
4.03%
Div growth
9.07%
Growth years
6
FCF payout
45.88%
Trailing P/E
718.26
Forward P/E
10.37
PEG
513.04
EPS growth
-10.50%
1 year return
5.01%
3 year return
0.86%
5 year return
-0.42%
10 year return
12.11%
Last updated: 2022-01-19

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open71.42
Daily high71.51
Daily low70.07
Daily Volume8.95M
All-time high122.21
1y analyst estimate75.77
Beta0.36
EPS (TTM)0.10
Dividend per share2.84
Ex-div date14 Dec 2021
Next earnings date27 Oct 2021

Downside potential

Loading...
Downside potential data
GILDS&P500
Current price drop from All-time high-42.37%-4.44%
Highest price drop-70.83%-56.47%
Date of highest drop7 Jun 19949 Mar 2009
Avg drop from high-24.38%-11.36%
Avg time to new high23 days12 days
Max time to new high1656 days1805 days

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.84
Dividend yield4.03%
Payout frequencyQuarterly
Maximum yield5.01%
Average yield3.63%
Minimum yield2.43%
Discount to avg yield10.01%
Upside potential11.13%
Yield as % of max yield80.44%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.03%
Current yield distribution27.54%
Yield at 100% (Min)2.43%
Yield at 90%2.87%
Yield at 80%3.02%
Yield at 50% (Median)3.75%
Yield at 20%4.16%
Yield at 10%4.32%
Yield at 0% (Max)5.01%

Dividend per share

Loading...
Dividend per share data
Years of growth6 years
CCC statusDividend Challenger
Dividend per share2.84
Payout frequencyQuarterly
Ex-div date14 Dec 2021
EPS (TTM)0.10
EPS (1y forward)6.79
EPS growth (5y)-10.50%
EPS growth (5y forward)1.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
GILDS&P500
DGR MR4.41%14.59%
DGR TTM4.41%0.48%
DGR 3 years7.60%3.88%
DGR 5 years9.07%4.73%
DGR 10 years-8.30%
DGR 15 years-5.82%
Time since last change announced352 days
EPS growth (5y)-10.50%
EPS growth (5y forward)1.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM2804.07%45.88%
Average--
Forward41.83%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E718.26
Price to OCF10.82
Price to FCF11.75
Price to EBITDA28.06
EV to EBITDA41.16

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.58
Price to Book4.11
EV to Sales5.25

FINANCIALS

Per share

Loading...
Per share data
Current share count1.25B
EPS (TTM)0.10
FCF per share (TTM)6.00

Income statement

Loading...
Income statement data
Revenue (TTM)24.69B
Gross profit (TTM)20.12B
Operating income (TTM)4.13B
Net income (TTM)123.00M
EPS (TTM)0.10
EPS (1y forward)6.79

Margins

Loading...
Margins data
Gross margin (TTM)81.48%
Operating margin (TTM)16.75%
Profit margin (TTM)0.50%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash4.36B
Net receivables4.57B
Total current assets13.99B
Goodwill8.33B
Intangible assets33.90B
Property, plant and equipment0.00
Total assets67.10B
Accounts payable4.37B
Short/Current long term debt27.69B
Total current liabilities10.24B
Total liabilities45.63B
Shareholder's equity21.47B
Net tangible assets-20.76B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)8.17B
Capital expenditures (TTM)650.00M
Free cash flow (TTM)7.52B
Dividends paid (TTM)3.45B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity0.68%
Return on Assets0.18%
Return on Invested Capital0.25%
Cash Return on Invested Capital15.15%
COMPANY DETAILS
GILD (Gilead Sciences Inc) company logo
Marketcap
88.35B
Marketcap category
Large-cap
Description
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Employees
13600
Investor relations
SEC filings
CEO
Daniel O'Day
Country
USA
City
Foster City
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
New York, NY, based Investment company Beech Hill Advisors, Inc. (Current Portfolio) buys Block Inc, The Walt Disney Co, Activision Blizzard Inc, Crown Castle International Corp, Gilead Sciences Inc, ...
January 19, 2022
Gilead Sciences Inc said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years, endang...
January 19, 2022
Investment company Townsend & Associates, Inc (Current Portfolio) buys The AES Corp, ConocoPhillips, Huntsman Corp, Gilead Sciences Inc, AbbVie Inc, sells PowerShares QQQ Trust Ser 1, Morgan Stanley, ...
January 18, 2022
FOSTER CITY, Calif., January 18, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2021 financial results will be released on Tuesday, February 1, after ...
January 18, 2022
Gilead Sciences uncovered a network that sold some $250 million of counterfeit versions of its HIV medications, a media report says.
January 18, 2022
Philadelphia, PA, based Investment company Addison Capital Co (Current Portfolio) buys Coterra Energy Inc, Intel Corp, General Motors Co, Activision Blizzard Inc, Match Group Inc, sells iShares S&P 50...
January 18, 2022
Gilead Sciences Inc said on Tuesday that tampered and counterfeit versions of its HIV treatments worth $250 million were sold to pharmacies over two years by a network of drug distributors and supplie...
January 18, 2022
Investment company N.E.W. Advisory Services LLC (Current Portfolio) buys VANGUARD BD IDX FD, Nicolet Bankshares Inc, Vanguard FTSE Emerging Markets ETF, Vanguard FTSE All-World Ex-US Small Capital Ind...
January 18, 2022
In the latest trading session, Gilead Sciences (GILD) closed at $71.77, marking a -0.15% move from the previous day.
January 17, 2022
Big pharmaceutical companies usually make big bucks. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). Keith Speights (AbbVie): There's so much to li...
January 16, 2022
Next page